A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.
about
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship.Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conferencePopulation pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of AmericaClinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance.The use and risks of antibiotics in critically ill patients.Update in Critical Care 2015.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Optimizing the Use of Antibacterial Agents in the Neonatal Period.Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units.Multidrug Resistant Pseudomonas Mycotic Pseudoaneurysm following Cardiac Transplant Bridged by Ventricular Assistant Device.[Therapeutic drug monitoring and individual dosing of antibiotics during sepsis : Modern or just "trendy"?]Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.Continuous β-Lactam Infusion to Optimize Antibiotic Use for Severe Sepsis. A Knife Cutting Water?Update in Critical Care Medicine: Evidence Published in 2016Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.Is there a role for continuous infusion of β-lactam antibiotics in severe sepsis?Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis.[Bacterial sepsis : Diagnostics and calculated antibiotic therapy].The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016).Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.Focus on antimicrobial use in the era of increasing antimicrobial resistance in ICU.Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment.Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?[Continuous infusion of beta-lactam antibiotics in severe sepsis (BLISS)].Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patientsOptimal infusion rate in antimicrobial therapy explosion of evidence in the last five years
P2860
Q26739860-939A97C7-7CB9-43FB-86B5-9F9454B4E68CQ30238578-1E10C3DF-CA2A-4E2C-AEF9-BAE29CCC3C49Q33640559-F848EDD2-C021-4563-95A0-1836A9FC4AD7Q36158212-F42F1451-5833-492B-8849-21158928BF9DQ36517624-AFDFAE9C-4908-44D3-AC63-84058B605759Q36760879-49B3DB9F-9A39-4996-AFCD-0765D55EBE12Q37220711-0E51989B-6E9D-437A-9B3A-FA57BC2BFEA4Q37642084-B59B6137-FEC2-4DC3-B89B-FD3284DAC443Q38672016-AA79C050-9C35-44B0-A4A3-B9FACC42382BQ38705266-54AA6127-F381-46CB-8252-90370CCA4F51Q38767901-0C77CB60-163A-4B6C-B70C-F4593C6AD230Q38883355-C231D19C-6B58-4847-BFFD-DEC171E3FB3AQ38896040-9FDA4F9D-6DC1-4E49-AF99-F2F0826ED453Q38922653-40B5093F-4EB1-464B-8352-013B8AC002E5Q40078698-784F66CF-1C8E-4C0D-95D1-569D8C912BBBQ40219976-A213017E-D514-4A00-8B12-650BD62D81C0Q40261115-7596B3B2-607D-4DC8-8DC2-F0BEB9C5039BQ40541397-062350AA-79BE-474E-98C3-A54A664E33F9Q40687385-F7A29B71-7EE4-4BCC-B023-33F26A9CCA2CQ40887955-4A828CEC-F5F8-4719-8C21-CC6F76D8F1FCQ42181731-6982F3F6-9942-4111-A8D0-1335D12B2DE5Q42247410-9A962828-E875-4AF1-BD8F-32084F5E3FEDQ42654588-E6A941B5-1C91-44C5-ACDE-1E8C5F47676FQ42751350-5BC0DEA2-D983-46B1-87C1-234C65FB9BA0Q47661746-895C50B9-7407-413E-830A-9A36A6A22187Q47745708-AC7A4D99-E56A-4455-8F43-AFADF854FA1CQ49589601-67B611CB-0189-44D9-B098-00550B360D94Q50052469-433AE05C-EB04-4ABC-BD99-B2AE31CDE65BQ50089280-7C67B173-EEB0-47A8-BB34-32B32999F69AQ53791273-390950F1-F5E2-40C4-9D08-61D0F1EF81F7Q54257517-E424A622-1F37-44A3-993D-19C851BA986BQ54261873-85B31F34-9085-486B-BDA4-8DF715E96BC5Q54568802-2E00D328-233E-473A-8E93-EA7C2F903A79Q58701649-FED7CABC-6ED5-4393-A801-14BCE774CD97Q58795590-12B6384E-B1B9-4197-91F1-FDB47E414EAE
P2860
A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A Multicenter Randomized Trial ...... tam Infusion in Severe Sepsis.
@en
type
label
A Multicenter Randomized Trial ...... tam Infusion in Severe Sepsis.
@en
prefLabel
A Multicenter Randomized Trial ...... tam Infusion in Severe Sepsis.
@en
P2093
P2860
P50
P1476
A Multicenter Randomized Trial ...... tam Infusion in Severe Sepsis.
@en
P2093
BLING II Investigators for the ANZICS Clinical Trials Group *
Charles Gomersall
Charudatt Shirwadkar
Glenn M Eastwood
John Myburgh
Steven A R Webb
Therese Starr
P2860
P304
P356
10.1164/RCCM.201505-0857OC
P407
P50
P577
2015-07-22T00:00:00Z